20190807 – Transgene Update EN
Category: Pexa-Vec
Transgene Provides Update on PHOCUS Study of Pexa-Vec in Liver Cancer Following Planned Interim Futility Analysis
20190802 PHOCUS Interim Analysis US
Transgene’s Lead Oncolytic Virus Pexa-Vec Triggers Strong Anti-Tumor Immunity after Intravenous Administration
20180604 PR ASCO Pexa-vec neoadjuvant data EN
Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity
Alan Anthoney, et al. ASCO 2018, June 2018 – Abstract available on the ASCO website Download the poster here Poster Presentation
Transgene to Present New Clinical Data on Oncolytic Virus Pexa-Vec at ASCO 2018
20180517 PR ASCO poster accepted EN
Transgene and Institut Bergonié Present a Poster on the METROmaJX Trial (Oncolytic Virus Pexa-Vec + Metronomic Cyclophosphamide) at ESMO 2017 Congress
20170907-ESMO-Metromajx-poster-EN
A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors
Maud Toulmonde, et al. ESMO 2017, September 11, 2017, 13:15 – 14:15, Hall 8 Download the poster here Poster Presentation
First Patient Dosed in a Phase 1/2 Trial of Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer
PR Pexa-Vec nivo EN
SillaJen and Transgene Announce the Enrollment of the First European Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer
20170424 PR PHOCUS FPI EU – EN
Transgene and Institut Bergonié Start the Phase 2 Part of the METROmaJX Trial
20170412 PR Metro-JX Ph2 EN
